Metformin Fails to Slow Low-Risk Prostate Cancer in Major Clinical Trial
A phase III trial of 408 men finds metformin does not delay prostate cancer progression during active surveillance — and may worsen outcomes in obese patients.
20 articles
A phase III trial of 408 men finds metformin does not delay prostate cancer progression during active surveillance — and may worsen outcomes in obese patients.
Clinical trial tested whether metformin could improve surgical outcomes and reduce hospital stays in non-diabetic older patients.
Major trial tests whether diabetes drug metformin can prevent frailty syndrome that affects millions of aging adults.
Six-month trial examines whether metformin treatment can improve telomere length and longevity gene expression in prediabetic individuals.
A 1.6-million-person cohort study finds metformin neither prevents AMD development nor slows progression to advanced disease stages.
Columbia University tested whether the diabetes drug metformin could slow memory loss in people with mild cognitive impairment.
Wake Forest study explores whether the diabetes drug metformin can trigger cellular changes linked to longevity in healthy people.
Une revue complète révèle les mécanismes polypharmacologiques de la metformine — de l'activation de AMPK au remodelage du microbiome intestinal — qui pourraient retarder le vieillissement et potentialiser l'immunothérapie anticancéreuse.
Clinical trial tested whether metformin could enhance resistance training benefits for muscle mass and strength in older adults.
Six-month trial finds diabetes drug metformin significantly reduces knee pain compared to placebo in people with osteoarthritis and excess weight.
60-patient trial explores whether metformin, combined with standard therapy, could slow Parkinson's progression through metabolic pathways.
Four-year study examined whether metformin could protect blood vessels in people with metabolic syndrome beyond its diabetes benefits.
A major review challenges the evidence behind metformin as a longevity drug, exposing methodological flaws in landmark studies.
A massive 860,000-patient multinational study finds metformin users face significantly lower delirium and mortality risk than those on DPP-4 inhibitors.
University of Pennsylvania researchers investigated how insulin resistance and testosterone interact in women after menopause.
Small trial tested whether the diabetes drug metformin could enhance immune response to pneumonia vaccine in aging adults.
New study reveals metformin's anti-aging effects depend entirely on whether you're insulin resistant or sensitive.
Carmot Therapeutics teste le CT-868, un nouvel agoniste double des récepteurs aux incrétines, pour la réduction de l'HbA1c chez des adultes en surpoids ou obèses atteints d'un diabète de type 2 mal contrôlé.
Research reveals how the diabetes drug metformin may extend lifespan and healthspan through multiple molecular pathways.
Small trial tests whether diabetes drug metformin can enhance immune response to flu vaccination in aging adults.